Adonis: Greece Must Support Innovation Like Angelos Stergiou and SELLAS Life Sciences

From New York to Nasdaq – when entrepreneurial success becomes a national cause and a blueprint for Greece.

I speak from the conviction that my experience in politics and public affairs has given me: when you see great achievements by Greeks abroad, you must not ignore or downplay them — you must defend and celebrate them.

This is what I thought when I visited New York and went to the offices of SELLAS Life Sciences Group, Inc. — the company founded and led by my friend Angelos Stergiou, which is now listed on Nasdaq under SLS and is developing innovative immunotherapies for cancer.

It wasn’t just a “politician visiting a friend” moment — it was a meeting with a Greek success story that transcends borders, showing how science, innovation, and free markets can genuinely change lives.

What SELLAS Does and Why It Matters

SELLAS Life Sciences is a biotech company focused on cutting-edge cancer therapies, including:

• Galinpepimut‑S (GPS), an immunotherapeutic vaccine targeting the WT1 protein, currently in clinical trials for acute myeloid leukemia (AML), with promising results that could improve survival in a patient group desperately in need of new treatments.
• SLS009, a selective CDK9 inhibitor, granted Orphan Drug Designation by the European Medicines Agency (EMA) for AML, showing strong Phase 2 results.

The company is expanding international partnerships and attracting major investors — including BlackRock increasing its stake by over 5%, demonstrating strong confidence in SELLAS on Nasdaq.

Responding to Malicious Comments

When I spoke publicly about my visit to Angelos Stergiou, some people — motivated by petty political jealousy — started posting sarcastic comments. One, from user @pavpol2222, was so emblematic that I felt compelled to defend Angelos publicly.

My defense was not just for a friend — it was for a Greek voice at the heart of global innovation. What is happening at SELLAS is not “luck.” It is the result of hard work, vision, and calculated risk. This is not a matter of envy but of national pride and political foresight.

Political and Geopolitical Implications

At a time when Greece struggles to strengthen research and innovation, we must support those who lead by example. SELLAS is not just a company — it’s a proof that Greeks can excel globally, attract investment, credibility, and technology back home.

The company’s solid funding, growing capitalization, and international partnerships show that Greece has an opportunity to foster a pro-innovation environment.

Capitalism, Free Markets, and the Greece I Envision

When Angelos Stergiou talks about faith in Capitalism, Free Markets, Innovation, and Risk, he is not speaking theoretically. He is speaking in results. And these results are:

• Life-saving therapies.
• International funding and recognition.
• Greek participation in global research.

This is the Greece I want — a Greece unafraid of big ideas, undistracted by envy, and unwilling to get trapped in petty political disputes.

The Political Stake in 2026

I hope that 2026 will be the year these ideas come to fruition — not only for the thousands of lives saved by clinical research but as a model for Greece itself. A Greece that supports innovation, encourages entrepreneurship, and promotes pride in Greeks who succeed globally.

You make us proud, Angelos. This is the Greece we want. — Not just in words, but in action.

Οταν είχα πάει στη Νέα Υόρκη μεταξύ των επισκέψεων μου εκεί, πήγα και στα γραφεία της SELLAS Life Sciences Group, Inc (SLS στο χρηματιστήριο της ΝΥ) του, εδώ και χρόνια φίλου μου κ. Αγγέλου Στεργίου. Μετά την ανάρτηση μου άρχισαν οι γνωστές εξυπνάδες που κυρίως προέρχονται από το… pic.twitter.com/xJiYoHcDtH

— Άδωνις Γεωργιάδης (@AdonisGeorgiadi) January 2, 2026

Source: pagenews.gr